Literature DB >> 12829768

Medicine. The need for a global HIV vaccine enterprise.

Richard D Klausner1, Anthony S Fauci, Lawrence Corey, Gary J Nabel, Helene Gayle, Seth Berkley, Barton F Haynes, David Baltimore, Chris Collins, R Gordon Douglas, Jose Esparza, Donald P Francis, N K Ganguly, Julie Louise Gerberding, Margaret I Johnston, Michel D Kazatchkine, Andrew J McMichael, Malegapuru W Makgoba, Giuseppe Pantaleo, Peter Piot, Yiming Shao, Edmund Tramont, Harold Varmus, Judith N Wasserheit.   

Abstract

A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829768     DOI: 10.1126/science.1086916

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  65 in total

1.  Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.

Authors:  Hua-Xin Liao; S Munir Alam; John R Mascola; James Robinson; Benjiang Ma; David C Montefiori; Maria Rhein; Laura L Sutherland; Richard Scearce; Barton F Haynes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  The power of giving.

Authors:  Caroline Hadley
Journal:  EMBO Rep       Date:  2004-08       Impact factor: 8.807

Review 3.  Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative.

Authors:  Timothy J Tucker; Gatsha Mazithulela
Journal:  BMJ       Date:  2004-08-21

4.  The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise.

Authors: 
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

5.  A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion.

Authors:  Nicolas Legrand; Gisela J van der Velden; Raphaël Ho Tsong Fang; Marc Douaisi; Kees Weijer; Atze T Das; Bianca Blom; Christel H Uittenbogaart; Ben Berkhout; Mireille Centlivre
Journal:  J Gen Virol       Date:  2012-05-30       Impact factor: 3.891

Review 6.  Health and economic benefits of an accelerated program of research to combat global infectious diseases.

Authors: 
Journal:  CMAJ       Date:  2004-11-09       Impact factor: 8.262

7.  A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

Review 8.  Research and development of new vaccines against infectious diseases.

Authors:  Marie Paule Kieny; Jean-Louis Excler; Marc Girard
Journal:  Am J Public Health       Date:  2004-11       Impact factor: 9.308

Review 9.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

10.  Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes.

Authors:  Jason A Wojcechowskyj; Levi J Yant; Roger W Wiseman; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.